• Skip to primary navigation
  • Skip to main content
Rebiotix Logo

Rebiotix

Powerful Therapy Delivered

  • Home
  • About
    • Senior Management
    • Stool Donor Program
    • Careers and Employment
  • Our Therapy
    • The Human Microbiome
    • Microbiota Restoration Therapy
    • Clostridioides difficile Infection
    • The Future of Microbiome-Based Therapeutics
  • Clinical Trials
    • RBX2660 Clinical Trials
    • RBX7455 Clinical Evaluation
    • Physician-sponsored Studies
    • Patient Resources
    • Expanded Access Policy
  • Science
    • Congress Publications
    • Manuscripts and Whitepapers
    • Related Evidence
  • Media
    • Latest Press Releases
    • Frequently Asked Questions
    • “Rebiotix” in the News
    • Conferences
    • Media Tools
    • Presentations & Videos
    • Contacts
  • Contact Us
  • Show Search
Hide Search

Placebo Response in a Randomized Controlled Trial of a Microbiota-based Drug Targeted at Recurrent C. difficile Infection: Results of the PUNCH CD 2

Sahil Khanna, MBBS, MS; Julie Messer, BS; Matt Adams, MS

Download this poster (146 KB)
Download the abstract (71 KB)

ACG 2016 Annual Scientific Meeting
October 15-19, 2016, Las Vegas, NV

Background

  • Largely uncontrolled studies of microbiota-based therapies for recurrent C. difficile infection (CDI) have demonstrated excellent efficacy.
  • Recently reported randomized, double-blinded, placebo-controlled studies of non-antibiotic therapies for multiply recurrent CDI, have found higher than anticipated placebo response rates.

Objective

  • To assess predictors of placebo response in a randomized, double-blinded, placebo-controlled trial of RBX2660, a microbiota-based drug targeted at the prevention of recurrent CDI.

Methods

  • Patients in the 3-arm PUNCH CD 2 trial were randomized 1:1:1 to receive either: 2 doses of RBX2660 (Group A); 2 doses of placebo (normal saline and cryoprotectant in the same proportions as RBX2660) (Group B); or 1 dose of RBX2660 and 1 dose of placebo (Group C), (Figure 1).
  • Therapies were administered via enema with doses 7 days apart.
  • Failures could cross over to open-label treatment and receive up to 2 doses of a CDI therapy, administered 7 days apart.
  • Success was defined as the absence of C. difficile-associated diarrhea at 8 weeks following completion of the last treatment.
  • Failure was defined as recurrence of CDI symptoms; a positive stool test; a need for CDI retreatment; and no other cause for CDI symptoms within 8 weeks.

RBX2660

  • Each dose of RBX2660 consisted of 50 gm of human stool/150 mL of suspension in a single-dose ready-to-use enema bag.
  • RBX2660 was stored frozen at ≤−80°C in a secure location at the manufacturer and then shipped frozen to the site in a temperature-controlled container.
  • RBX2660 was manufactured using standardized, quality-controlled processes.

Results

  • In the intention-to-treat population, a total of 44 patients (median age: 62; range: 19-92 years; 68.2% female) were randomized to the placebo arm.
  • Of the patients treated with placebo, 45.5% (20/24) responded and 54.5% (24/44) failed.
  • There were no significant differences in the age, gender, number of previous CDI episodes, or antibiotics used to control C. difficile symptoms prior to enrollment between patients who responded to placebo and those who did not (Table 1).
  • All 24 patients who failed placebo (experienced recurrence) went on to receive open-label treatment with RBX2660. Of these patients, 87.5% (21/24) were successful when treated with RBX2660.

Conclusions

  • The placebo response rate in the PUNCH CD 2 was higher than originally anticipated.
  • There were no differences in the patient profiles, prior history of CDI and its treatment between the patients in the PUNCH CD 2 who responded to placebo and those who did not.
  • 87.5% of patients who failed placebo were successful with open-label RBX2660.
  • The placebo response rate in the PUNCH CD 2 study is consistent with other recent studies of drugs and therapies for recurrent CDI (Tables 2 and 3).
  • Further studies are needed to explore reasons for the placebo response.

References

  1. Kelly CR, Khoruts A, Staley C, et al. Effect of fecal microbiota transplantation on recurrence in multiply recurrent Clostridium difficile infection: A randomized trial. Ann Intern Med. 2016 Aug 23. Epub ahead of print.
  2. Seres Therapeutics announces interim results from SER-109 Phase 2 ECOSPOR study in multiply recurrent Clostridium difficile infection [news release]. Cambridge, MA: Seres Therapeutics, Inc. communication; July 29, 2016. http://ir.serestherapeutics.com/phoenix.zhtml?c=254006&p=irol-newsArticle&ID=2190006. Accessed August 8, 2016.
  3. Wilcox M, Gerding D, Poxton I, et al. Bezlotoxumab (BEX) alone and with actoxubab (ACT) for prevention of recurrent C. difficile infection (rCDI) in patients on standard of care (SoC) antibiotics: integrated results of 2 Phase 3 Studies (MODIFY 1 and MODIFY II). Abstract presented at ID Week 2015. October 7-11, 2016, San Diego, CA.

Microbiota Restoration Therapy Abstracts, Microbiota Restoration Therapy Posters Abstracts, Posters

Interested in Becoming a Stool Donor? Learn More

Rebiotix

  • Copyright © 2022 Rebiotix, Inc.
  • A Ferring Company
  • Privacy Policy
  • Terms of Use
  • Sitemap
  • Contact Us

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.
SAVE & ACCEPT